SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma cells through modulation of NF-κB signaling.

Biochem Biophys Res Commun

Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing 100850, PR China; Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, PR China. Electronic address:

Published: May 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

SUMO/sentrin specific protease 1 (Senp1) is an important regulation protease in the protein sumoylation, which affects the cell cycle, proliferation and differentiation. The role of Senp1 mediated protein desumoylation in pathophysiological progression of multiple myeloma is unknown. In this study, we demonstrated that Senp1 is overexpressed and induced by IL-6 in multiple myeloma cells. Lentivirus-mediated Senp1 knockdown triggers apoptosis and reduces viability, proliferation and colony forming ability of MM cells. The NF-κB family members including P65 and inhibitor protein IkBα play important roles in regulation of MM cell survival and proliferation. We further demonstrated that Senp1 inhibition decreased IL-6-induced P65 and IkBα phosphorylation, leading to inactivation of NF-кB signaling in MM cells. These results delineate a key role for Senp1in IL-6 induced proliferation and survival of MM cells, suggesting it may be a potential new therapeutic target in MM.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2015.03.047DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
12
senp1 inhibition
8
myeloma cells
8
demonstrated senp1
8
senp1
6
cells
5
inhibition induces
4
induces apoptosis
4
apoptosis growth
4
growth arrest
4

Similar Publications

Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.

View Article and Find Full Text PDF

Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.

View Article and Find Full Text PDF

AI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignancies.

Eur J Cancer

August 2025

Emory University, Atlanta, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA; Atlanta Veterans Administration Medical Center, Atlanta, USA. Electronic address:

Background: Early detection of hematological malignancies improves long-term survival but remains a critical challenge due to heterogeneity in clinical presentation. Chronic inflammation is a key driver in hematologic cancers and is known to induce compensatory microvascular changes. High-resolution, non-invasive retinal imaging can allow the quantification of microvascular changes for the early detection of hematological malignancies.

View Article and Find Full Text PDF